ICMR’s process is exactly in accordance with globally accepted norms to fast-track the vaccine development for diseases of pandemic potential wherein human and animal trials can continue in parallel: ICMR on #COVID19 vaccine candidate developed by Bharat Biotech International Ltd
India's premier medical body ICMR has said 12 clinical trial sites for the indigenous Covaxin, being developed in collaboration with the Hyderabad-based Bharat Biotech and the National Institute of Virology (NIV), have been identified.
Inactivated #COVID19 vaccine candidate has been developed by Bharat Biotech in collaboration with @ICMRDELHI . #ICMR supporting clinical development as vaccine candidate appears promising; based on in-depth scrutiny, DCGI accords permission to conduct phase 1, 2 clinical trial
Drug Controller General of India gives approval for human clinical trials of #COVAXIN , the 1st potential #Covid_19 Vaccine developed in India. ▪️ The potential vaccine has been developed by Hyderabad-based Bharat Biotech, in association with Indian Council of Medical Research.
Drug Controller General of India gives approval to Hyderabad based Bharat Biotech for phase I & II human clinical trials of ‘Covaxin’ to develop indigenous vaccine for #COVID19 . Bharat Biotech Chairman Dr Krishna Ella says, "It was developed in partnership with ICMR & NIV Pune."